Fibrogen Inc.'s $326 million offering on the heels of Street-pleasing phase II data with pamrevlumab (previously FG-3019) in idiopathic pulmonary fibrosis (IPF) turned investor eyes to other prospects for the indication, prompting comparisons between them – such as they could be made – and attempts to stack pipeline candidates against two marketed products.